Fiche du document
- doi: 10.1016/j.jclinepi.2018.05.002
- issn: 0895-4356
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jclinepi.2018.05.002
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29777797
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1878-5921
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_1A0984F080467
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Medications Medicaments Prescription drugs Medicines (Drugs) Pharmaceuticals Medicine (Drugs)Citer ce document
N. Abolhassani et al., « Polypharmacy, defined as taking five or more drugs, is inadequate in the cardiovascular setting. », Serveur académique Lausannois, ID : 10.1016/j.jclinepi.2018.05.002
Métriques
Partage / Export
Résumé
By how much polypharmacy (defined by number of drugs) differs from polyactive ingredient use (defined by the number of pharmacologically active ingredients) has not been assessed. To compare the extent of polypharmacy vs. polyactive ingredients among patients taking cardiovascular (CV) medicines. Prospective, 10-year follow-up study conducted among 880 participants of the CoLaus study taking CV drugs at baseline. Polypharmacy was defined as the use of five or more CV medicines; polyactive ingredient use was defined as the use of five or more pharmacologically active CV ingredients. The prevalence of polypharmacy increased from 1.4% (0.7-2.4) (prevalence rate [95% confidence interval]) at baseline to 11.9% (9.9-14.3) at follow-up, and the prevalence of polyactive ingredients increased from 2.4% (1.5-3.6) at baseline to almost 17.6% (15.2-20.3) at follow-up. The prevalence of combination drugs increased from 15.7% (13.3-18.3) at baseline to 25.9% (23-28.9) at follow-up, and the prevalence of three-component combination use increased from 0.1% (0.0-0.6) at baseline to 2.3% (1.4-3.5) at follow-up. At baseline, nine of 21 participants on polyactive ingredients were not considered as being on polypharmacy; at follow-up, the rate was 50 of 155 participants. Among individuals taking CV drugs, polypharmacy as defined by the number of drugs underestimates the prevalence of individuals taking five or more pharmacologically active drugs. Polypharmacy should no longer be based on the number of drugs but on the number of pharmacologically active drugs.